RxDoctor Payments Data

Carlos Pernas

Physician Assistant · Loxahatchee, FLNPI 1275511388

Payments from drug & device makers

$2,666in general payments, 2019–2025

Across 134 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$548
  • Antares Pharma, Inc.$491
  • Johnson & Johnson$300
  • Sumitomo Pharma America, Inc.$186
  • Verity Pharmaceuticals Inc.$144
  • Endo Pharmaceuticals Inc.$130
  • plus $867 from 19 others

What the payments were for

  • Food & beverage$2,40390%
  • Education$26310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,666 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$40,060
Medicare patients
218
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide47$649,337
OrgovyxRelugolix143$366,780
GemtesaVibegron75$63,978
MyrbetriqMirabegron64$40,312
Silodosin161$16,379
XyostedTestosterone Enanthate17$14,797
Dutasteride326$9,023
Tamsulosin Hcl1,135$8,983
Alfuzosin Hcl ErAlfuzosin Hcl407$7,707
Solifenacin Succinate95$7,069
Tolterodine Tartrate ErTolterodine Tartrate36$4,569
Testosterone Cypionate69$3,633
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst231$2,896
Desmopressin Acetate16$2,821
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip122$2,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$548$689,649111 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$186$430,757218 claims
Antares Pharma, Inc.Xyosted$491$14,79717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Loxahatchee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →